TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ketanserin After LSD Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 25 and 65 years old~2. Sufficient understanding of the German language~3. Understanding of procedures and risks associated with the study~4. Willing to adhere to the protocol and signing of the consent form~5. Willing to refrain from the consumption of illicit psychoactive substances during the study~6. Abstaining from xanthine-based liquids and foods from the evenings prior to the study sessions to the end of the study days~7. Willing not to operate heavy machinery within 48 hours after substance administration~8. Willing to use double-barrier birth control throughout study participation~9. Body mass index between 18-29 kg/m2~Exclusion Criteria:~1. Chronic or acute medical condition~2. Current or previous major psychiatric disorder~3. Psychotic disorder or bipolar disorder in first-degree relatives~4. Hypertension (\>140/90 mmHg) or hypotension (SBP\<85 mmHg)~5. Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months~6. Pregnancy or current breastfeeding~7. Participation in another clinical trial (currently or within the last 30 days)~8. Use of medication that may interfere with the effects of the study medication~9. Tobacco smoking (\>10 cigarettes/day)~10. Consumption of alcoholic beverages (\>20 drinks/week)

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 100 μg LSD + Ketanserin placebo (Type: EXPERIMENTAL): None
- 100 μg LSD + Ketanserin (40mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pediatric oncology patients undergoing a lumbar puncture in the Pediatric Sedation Suite; patients may or may not be receiving intrathecal chemotherapy~Exclusion Criteria:~Patients undergoing additional procedures during the same anesthetic such as bone marrow aspirate or biopsy will be excluded because they will likely require higher doses of propofol than those undergoing LP alone Patients who are allergic to or not tolerant of EMLA cream, propofol, or fentanyl will be excluded Patients who are pregnant will be excluded Patients having their LPs done by students will be excluded

- Gender: ALL
- Minimum Age: None
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (EMLA) (Type: EXPERIMENTAL): Patients receive topical EMLA cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
- Arm II (placebo) (Type: ACTIVE_COMPARATOR): Patients receive topical placebo cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetic Comparison of Exforge® and G-0081 in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers between the ages of 20 and 50 and within 20% of their ideal body weight, without congenital abnormality or chronic disease~Exclusion Criteria:~* History of cardiovascular, pulmonary, renal, endogenous, gastrointestinal, hematologic, neurologic or hemorrhagic disease;~* Clinically significant findings on routine laboratory (hematology, serum chemistry and urinalysis) or ECG tests;~* Use of prescription drugs in the 14 days immediately prior to starting the study that had the potential to interact with the study medication;~* Use of any substance that could induce or inhibit drug metabolism enzymes

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Test and reference formulations (Type: EXPERIMENTAL): Test formulation and reference formulation given orally 14 days apart in a fasted state

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed soft tissue angiosarcoma or lymphangiosarcoma~  * Locally advanced or metastatic disease~ * Unresectable disease~* Angiosarcomas in previously irradiated areas allowed provided disease is clearly progressive~* Measurable disease~* No Kaposi's sarcoma~PATIENT CHARACTERISTICS:~Age~* 18 to 70~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count \> 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~Hepatic~* Bilirubin \< 3 times upper limit of normal (ULN)~* SGOT and SGPT \< 2.5 times ULN~* No severe liver failure~Renal~* Creatinine clearance \> 60 mL/min~* No severe kidney failure~Cardiovascular~* LVEF ≥ 50%~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No weight loss ≥ 20% of body weight prior to illness~* Patient must be amenable to receiving care during the day~* No HIV positivity~* No clinical neuropathy~* No known allergy to study drug or to any of its components (e.g., Cremophor EL)~* No other progressive malignant tumor~* No chronic illness (somatic or psychiatric) that would preclude study compliance and follow-up~* No psychological, geographical, or social reason that would preclude study follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No more than 2 prior courses of chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~Surgery~* Not specified~Other~* No other concurrent anticancer therapy~* No concurrent participation in another therapeutic investigational study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel (Type: EXPERIMENTAL): Paclitaxel 80 mg/m² Day 1, Day 8 and Day 15. No treatment on Day 22.~1 cycle = 28 days.~Treatment duration: 6 cycles (=6 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Cord Stimulation Frequency Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old at the time of informed consent~* Willing and able to provide a signed and dated informed consent~* Capable of comprehending and consenting in English~* Willing and able to comply with all study procedures, study visits, and be available for the duration of the study~* On a stable dose (no new, discontinued or changes in) of all prescribed pain medications and willing/able to maintain or only decrease the dose of all prescribed pain medications~* Tried appropriate conventional medical management for their pain~* Not indicated for additional surgical treatment in the opinion of the referring physician or spinal surgeon~* Undergone previous spinal surgery~* Diagnosed with FBSS with appropriate pain score~* Primary pain at appropriate spinal level~Exclusion Criteria:~* Has an active implanted device, whether turned on or off~* Displays current signs of a systemic infection~* Pregnant or lactating, inadequate birth control, or the possibility of pregnancy during the study~* Has untreated major psychiatric comorbidity~* Has serious drug-related behavioral issues~* Has neurological abnormalities unrelated to Failed Back Surgery Syndrome~* Diagnosed with Raynaud disease~* Diagnosed with Fibromyalgia~* Has any active malignancy or has been diagnosed with cancer and has not been in remission for at least 1 year prior to screening~* Has secondary gains which, in the opinion of the investigator, are likely to interfere with the study~* Participating or planning to participate in another clinical trial~* Has characteristics/limits of household or close contacts involved in study (eg, family member already a study participant where blind could be broken)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sham (Type: SHAM_COMPARATOR): Frequency Setting - Sham
- 1200 Hz (Type: EXPERIMENTAL): Frequency Setting - 1200 Hz
- 3030 Hz (Type: EXPERIMENTAL): Frequency Setting - 3030 Hz
- 5882 Hz (Type: EXPERIMENTAL): Frequency Setting - 5882 Hz

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Experience dose-limiting symptoms at or before the challenge dose of peanut protein on screening and not experiencing dose-limiting symptoms to placebo as defined in the protocol~* Serum Immunoglobulin E (IgE) to peanut of ≥10 kUA/L and/or a skin prick test (SPT) to peanut ≥8 mm compared to a negative control~* Participants/legal guardians must be trained on the proper use of the epinephrine autoinjector device to be allowed to enroll in the study~* Participants with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study~Key Exclusion Criteria:~* History of other chronic disease (other than asthma, Atopic Dermatitis (AD), or allergic rhinitis) requiring therapy (eg, heart disease, diabetes, hypertension) that would represent a risk to participant's health or safety in this study or ability to comply with study protocol~* History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock~* History of eosinophilic Gastrointestinal (GI) disease~* Asthma at time of enrollment with any of the following:~  * Forced Expiratory Volume 1 Second (FEV1) \<80% of predicted or ratio of FEV1 to forced vital capacity (FEV1/FVC) \<75% of predicted with or without controller medications~ * Inhaled corticosteroids (ICS) dosing of daily fluticasone (or equivalent ICS based on NHLBI dosing chart)~ * One hospitalization in the past year for asthma~ * Emergency room visit for asthma within 6 months prior to screening~* Use of systemic corticosteroids within 2 months prior to screening~* Use of other forms of allergen immunotherapy or immunomodulatory therapy within 3 months prior to screening~* Use of any agents known or likely to interact with epinephrine (eg, beta-blockers, angiotensin converting enzyme-inhibitors, tri-cyclic antidepressants, or other drugs), within 3 weeks prior to screening~* Allergy to oat (placebo in DBPCFC)~Note: Other protocol Inclusion/Exclusion Criteria apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- dupilumab + AR101 (Type: EXPERIMENTAL): Participant randomization of a ratio of 2 active dupilumab arms
- placebo matching dupilumab + AR101 (Type: EXPERIMENTAL): Participant randomization of a ratio of 1 placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PXVX0200 (CVD103-HgR) vs Shanchol in Mali

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand the study and give consent (either written or through a process that involves audio tapes explaining all aspects of the study and the consent form in local languages \[Bambara and French\] followed by making a mark and signature by a literate witness)~* Healthy men or women, age 18 to 45 years (inclusive) without significant medical history~* Women of child-bearing potential must have negative urine pregnancy test at baseline, prior to vaccination. They must also be willing to use adequate birth control for the duration of the 28-day study and have additional pregnancy tests if indicated. Effective methods of birth control for this study include abstinence, intrauterine device (IUD), oral or depot contraceptive, or barrier plus spermicide~* Willingness to remain in the study area until at least 42 days after receipt of the first vaccine dose~Exclusion Criteria:~* Health care workers who have direct contact with patients who are immune deficient, HIV-positive, or have an unstable medical condition~* Clinically significant history of immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder requiring hospitalization, current drug or alcohol abuse~* History of an abnormal stool pattern or regular use of laxatives~* Previously received a licensed or investigational cholera vaccine~* History of cholera illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PXVX0200 10E8 then placebo (Type: EXPERIMENTAL): PXVX0200 10E8 on day 0; Placebo on day 14
- Placebo, then PXVX0200 10E8 (Type: EXPERIMENTAL): Placebo on day 0; PXVX0200 10E8 on day 14
- PXVX0200 10E9 then Placebo (Type: EXPERIMENTAL): PXVX0200 10E9 on day 0; Placebo on day 14
- Placebo then PXVX0200 10E9 (Type: EXPERIMENTAL): Placebo on day 0; PXVX0200 10E9 on day 14
- Shanchol (Type: ACTIVE_COMPARATOR): Two doses of Shanchol, on day 0 and day 14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postmenopausal Women and Their Endothelium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Early post-menopausal women who are within 1-6 years following their final menstrual cycle~* Late post-menopausal women who are beyond 6 years following their final menstrual cycle~Exclusion Criteria:~* Individuals with any overt cardiovascular, metabolic, hematologic, pulmonary, renal, musculoskeletal, and/or neurological disease(s).~* Users of any tobacco and/or nicotine products (smokers, chewing tobacco, nicotine-containing patches/gum, smokeless cigarettes)~* Individuals with a BMI \> 35~* Individuals with resting blood pressure \> or = 130/80 mm Hg~* Individuals with high blood lipids (total cholesterol \> or = 240 mg/dl, LDL \> or = 160 mg/dl, triglycerides \> or = 200 mg/dl).~* Postmenopausal women with hyperglycemia (fasting glucose \> or = 110 mg/dl and HbA1c \>6.0%).~* Individuals taking any of the following medications:~  1. blood pressure lowering medication (e.g., beta blockers, ACE inhibitors, angiotensin antagonists, calcium channel blockers, diuretics)~ 2. lipid- lowering medication (e.g., statins)~ 3. nitrates (e.g. nitroglycerin) for angina~ 4. phosphodiesterase inhibitors (e.g., Viagra)~ 5. anti-Inflammatory drugs~* Individuals taking hormone therapy

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Nitrate rich beetroot juice (Type: ACTIVE_COMPARATOR): Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
- Nitrate depleted beetroot juice (Type: PLACEBO_COMPARATOR): Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exteriorized Versus In Situ Uterine Repair at Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy pregnant women scheduled for elective cesarean delivery~Exclusion Criteria:~* ASA III or IV patients~* Patient with conditions that predispose to uterine atony and post partum hemorrhage

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Medically stable adults, aged 18-49 years.~* Provided informed consent prior to any study procedures.~* Able to comply with all study procedures.~* Available for follow-up for the duration of the influenza season.~* Women of child-bearing potential had a negative urine pregnancy test at the time of randomization and were willing to use an adequate form of contraception during the course of the study.~Exclusion Criteria:~* Any history of immunodeficiency or treatment with immunosuppressive medications. (Use of inhaled steroids or of topical steroids was not considered immunosuppressive; receipt of systemic glucocorticosteroids was not allowed if daily intake was \>10 mg of prednisone or equivalent).~* Presence of high-risk conditions or other characteristics considered to be indications for influenza vaccination, as defined by the Advisory Committee on Immunization Practices (ACIP).~* Acute febrile illness (defined as having a temperature ≥100degreesF) or upper respiratory tract illness within 72 hours of vaccination.~* Use of experimental vaccines or any influenza vaccine after May 31st 2004 for the 2005 Southern Hemisphere or 2004 to 2005 Northern hemisphere epidemic seasons.~* Use of any experimental medication within 30 days prior to study vaccination~* Women who were pregnant or breast-feeding.~* Subjects with a history of Guillain-Barré syndrome.~* Receipt of parenteral immunoglobulin within 30 days prior to study vaccination.~* Any acute or chronic condition that, in the opinion of the investigator, would render vaccination unsafe or interfere with the evaluation of response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Low Dose (Type: EXPERIMENTAL): Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2) and 15μg from A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
- Full Dose (Type: EXPERIMENTAL): Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2), A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% Sodium Chloride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Montelukast in Rhinitis and Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria will include:~1. Age 16 to 65.~2. History of allergic rhinitis.~3. The ability to be placed on placebo without significant compromise in the quality of life.~4. General good health.~5. Ability to comply with the protocol and sign an informed consent.~6. Have daytime sleepiness by history.~7. Have poor sleep by history.~8. Have fatigue by history.~9. Have a skin test or RAST test to a perennial allergen (indoor mold, dog, cat, mite) with correlating symptoms.~Exclusion Criteria:~1. Age fewer than 16 or over 65 years.~2. A history of sleep apnea.~3. Atopic diseases other than allergic rhinitis, such as atopic dermatitis or asthma.~4. Non-allergic rhinitis.~5. Obesity.~6. Inability to tolerate montelukast.~7. Significant other diseases as determined by the investigator.~8. Use of a research medication within 30 days.~9. Use of a nasal steroid or topical antihistamine or decongestant within 30 days.~10. Use of beta-blockers, antidepressants, oral decongestants, oral steroids, or H2-blockers.~11. Excessive use of alcohol or drug abuse.~12. Inability to stop medication use during run-in period.~13. Use of an oral antihistamine within 1 week of enrollment.~14. Failed to have benefit when montelukast was used for rhinitis or asthma in the past

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- montelukast (Type: ACTIVE_COMPARATOR): montelukast 10 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete